Follow
nizar bahlis
nizar bahlis
Associate Professor, University of Calgary
Verified email at ucalgary.ca
Title
Cited by
Cited by
Year
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ...
New England Journal of Medicine 375 (14), 1319-1331, 2016
15722016
Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma
P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ...
New England Journal of Medicine 374 (17), 1621-1634, 2016
12102016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ...
The Lancet 387 (10027), 1551-1560, 2016
9672016
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ...
New England Journal of Medicine 371 (10), 906-917, 2014
9072014
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ...
New England Journal of Medicine 380 (22), 2104-2115, 2019
8682019
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ...
Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012
8072012
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ...
Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016
4922016
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ...
Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014
4452014
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
4342016
Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ...
New England Journal of Medicine 387 (6), 495-505, 2022
4042022
Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells
JM Grad, NJ Bahlis, I Reis, MM Oshiro, WS Dalton, LH Boise
Blood, The Journal of the American Society of Hematology 98 (3), 805-813, 2001
3682001
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
R Vij, M Wang, JL Kaufman, S Lonial, AJ Jakubowiak, AK Stewart, ...
Blood, The Journal of the American Society of Hematology 119 (24), 5661-5670, 2012
3122012
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
T Facon, MA Dimopoulos, A Dispenzieri, JV Catalano, A Belch, M Cavo, ...
Blood, The Journal of the American Society of Hematology 131 (3), 301-310, 2018
2792018
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label …
S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ...
The Lancet 396 (10262), 1563-1573, 2020
2522020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ...
Leukemia 34 (7), 1875-1884, 2020
2442020
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma
NJ Bahlis, J McCafferty-Grad, I Jordan-McMurry, J Neil, I Reis, ...
Clinical cancer research 8 (12), 3658-3668, 2002
2402002
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
MA Dimopoulos, J San-Miguel, A Belch, D White, L Benboubker, G Cook, ...
haematologica 103 (12), 2088, 2018
2362018
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
NC Munshi, H Avet-Loiseau, KC Anderson, P Neri, B Paiva, M Samur, ...
Blood advances 4 (23), 5988-5999, 2020
2352020
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
D Reece, KW Song, T Fu, B Roland, H Chang, DE Horsman, A Mansoor, ...
Blood, The Journal of the American Society of Hematology 114 (3), 522-525, 2009
2322009
An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
R Vij, DS Siegel, S Jagannath, AJ Jakubowiak, AK Stewart, K McDonagh, ...
British journal of haematology 158 (6), 739-748, 2012
2232012
The system can't perform the operation now. Try again later.
Articles 1–20